{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"DLTs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and included the below if considered by the investigator to be related to AMG 176: Grade 3 or higher non-hematological or a Grade 4 hematologic adverse event (AE) during the DLT observation period in Part 1.\n\nCTCAE Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, and Grade 5 results in death.","groups":[{"description":"Participants received IV AMG 176 at dose level 1 once a week in 28-day cycles. Treatment was planned until disease progression or unacceptable toxicity.","id":"OG000","title":"Part 1A Dose Exploration: AMG 176 Dose Level 1"},{"description":"Participants received IV AMG 176 at dose level 1 on cycle 1 day 1 and then dose level 2 from cycle 1 day 8 and once a week thereafter (each cycle = 28 days). Treatment was planned until disease progression or unacceptable toxicity.","id":"OG001","title":"Part 1A Dose Exploration: AMG 176 Dose Level 1 Then Dose Level 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"DLT-evaluable participants were those who experienced a DLT during the DLT evaluation period or if they received 75% of the planned doses of AMG 176 and completed the DLT evaluation period.","reportingStatus":"POSTED","timeFrame":"Day 1 to day 28 of cycle 1 (each cycle was 28 days)","title":"Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)","type":"PRIMARY","unitOfMeasure":"Participants"}